Divis Labs Gears Up for Q3 Reveal on 11th February; Check Key Expectations Here

Divis Labs 's Q3 results FY26 are scheduled to be announced on 11th February 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Divis Labs Q3 Results 2026 Preview

• Divis Labs' revenue is expected to be in the range of ₹2,401 crore, a 25.4% YoY increase. 
• Profit After Tax, or PAT, is projected to fall 6% YoY. 
• Net profit is ₹21.60 crore, down 6% YoY 
• EBITDA to rise 18%

Divis Labs Share Performance 

• Over the past six months, Divis Labs' share price has risen by 1.05% to ₹71.22.
• Moreover, over the past year, the stock has increased by 5.05%.
• Despite this weak short-term performance, Divis Labs' stock has delivered a financially sound 51.37% return over the past 5 years.
• As of 10th February 2026, the stock traded at ₹71.22 per share.

About Divis Labs

Divi’s Laboratories Limited is a leading Indian pharmaceutical company headquartered in Hyderabad, specializing in the manufacture of active pharmaceutical ingredients (APIs), intermediates, and nutraceutical ingredients. Founded in 1990, the company serves global markets including the US and Europe, supplying products to major pharmaceutical companies across more than 100 countries.

Key Factors to Watch for Divis Labs  Q3 Results FY26

• Revenue Growth: Performance of API, custom synthesis, and nutraceutical segments across domestic and export markets.
• Profitability & Margins: Trends in EBITDA and PAT margins reflecting raw material costs and operating efficiency.
• Custom Synthesis & Product Mix: Contribution from high-margin custom manufacturing and new product opportunities.
• Capacity Utilisation & Expansion: Utilisation levels at key facilities and impact of new capacities on volumes.
• Management Outlook & Export Demand: Commentary on global demand, pricing environment, and future growth strategy.

Final Thoughts

Divis Labs will announce its Q3 FY26 results on 11th February 2026. Analysts expect 25.4% revenue growth, a 6% fall in PAT, and a 18% rise in EBITDA. Divis Labs focuses export-led revenue growth, margin stability, strength in custom synthesis business, efficient capacity utilisation, and management guidance on global demand and pricing trends.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

Alfred Herbert India Ltd Q3 Results FY26 Preview: PAT falls 3%

Salora International Q3 Results FY26 Preview: PAT falls 18.54%

Kuantum Papers Q3 Results FY26 Preview: PAT falls 29.85%

AK Capital Services Ltd Q3 Results FY26 Preview: PAT falls 16.86%

Glance Finance Q3 Results FY26 Preview: PAT rises 58.48%